Cytomegalovirus (CMV): Epidemiology Forecast to 2027

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Cytomegalovirus (CMV) is a common virus belonging to the Herpesviridae family. CMV is present in up to 60% of adults in high-income countries and up to 100% of adults in low- and middle-income countries. In individuals with healthy immune systems, CMV infections are typically asymptomatic, and the virus establishes a lifelong latent infection. Certain populations, such as people living with human immunodeficiency virus (HIV), solid organ transplant (SOT) patients, allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, and infants infected in utero, are vulnerable to symptomatic disease caused by primary CMV infections or reactivation. CMV disease may also occur in critically ill immunocompetent patients. Depending on the population, CMV disease can present as end-organ disease (infection and symptoms in lung, gastrointestinal (GI) tract, liver, retina, or other organs), CMV syndrome (fever, fatigue, leukopenia, and/or thrombocytosis), or congenital CMV (cCMV) (symptoms ranging from mild manifestations to premature birth and neurologic sequelae).

This forecast is strengthened by a thorough review of historical data and current literature on CMV disease in the 7MM. In addition, the use of consistent methodology for calculation of CMV cases allows for meaningful comparisons between markets. This analysis also provides detailed segmentation of CMV disease by age, sex, and population at risk. Additional segmentations on disease manifestation, transplant patient serostatus, and seroprevalence in pregnant women and the general population can be found in the GlobalData Cytomegalovirus (CMV) Epidemiology Forecast Model.

The following data describes epidemiology of CMV cases. In 2017, there were 9,691 diagnosed incident cases of CMV disease in the 7MM. The US had the most cases (5,885), while Japan had the fewest (271). GlobalData epidemiologists forecast that the number of CMV cases in the 7MM will increase to 10,704 in 2027, at an Annual Growth Rate (AGR) of 1.05%. All countries besides Germany are expected to see an increase in CMV cases. HIV patients made up the greatest burden of CMV cases in the 7MM in 2017 (3,734 cases), followed closely by SOT patients (3,696 cases). cCMV accounted for the fewest cases (979).

Scope

The Cytomegalovirus (CMV) Epidemiology Forecast Report and Epidemiology Forecast Model provide an overview of the risk factors and global trends of CMV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report provides an overview of the risk factors, comorbidities, and global and historical trends for CMV disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0–10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.

The CMV epidemiology forecast report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Forecast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The CMV Epidemiology Forecast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CMV market.

Quantify patient populations in the global CMV market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CMV therapeutics in each of the markets covered.

Understand magnitude of CMV population by population at risk.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 CMV: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 CMV Disease in Diagnosed Prevalent HIV Patients

3.3.2 CMV Disease in SOT Patients

3.3.3 CMV Disease in Allo-HSCT Patients

3.3.4 Congenital CMV Disease

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for CMV (2017–2027)

3.5.1 Diagnosed Incident Cases of CMV

3.5.2 Age-Specific Incident Cases of CMV

3.5.3 Sex-Specific Diagnosed Incident Cases of CMV

3.5.4 CMV Diagnosed Incident Cases by Population at Risk

3.5.5 HIV-CMV

3.5.6 SOT Patients

3.5.7 SOT-CMV

3.5.8 HSCT Patients

3.5.9 HSCT-CMV

3.5.10 Diagnosed Incident Cases of Congenital CMV

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for CMV

Figures

Figure 1: 7MM, Diagnosed Incident Cases of CMV, Both Sexes, All Ages, 2017 and 2027

Figure 2: Age-Standardized Diagnosed Incidence of CMV Disease, All Ages, 2017

Figure 3: Case Flow Map

Figure 4: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of HIV-CMV

Figure 5: Sources Used and Not Used for Calculations of SOT Patients

Figure 6: Sources Used and Not Used for Calculations of Diagnosed Incident Cases of SOT-CMV

Figure 7: Sources Used and Not Used for Calculations of Allo-HSCT Patients and Diagnosed Incident Cases of HSCT-CMV

Figure 8: Sources Used and Not Used for Calculations of Live Births and cCMV Cases

Figure 9: Diagnosed Incident Cases of CMV, 7MM, Men and Women, All Ages, 2017

Figure 10: 7MM, Age-Specific Diagnosed Incident Cases of CMV Disease, Men and Women, 2017

Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of CMV Disease, All Ages, 2017

Figure 12: 7MM, Diagnosed Incident Cases of CMV Disease by Population at Risk, Men and Women, All Ages, 2017

Figure 13: 5EU and Japan, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017–2027

Figure 14: US, Diagnosed Incident Cases of HIV-CMV, Men and Women, All Ages, 2017–2027

Figure 15: 7MM, SOT Patients, Men and Women, All Ages, 2017–2027

Figure 16: 7MM, Diagnosed Incident Cases of SOT-CMV, Men and Women, All Ages, 2017–2027

Figure 17: 7MM, Allo-HSCT Patients, Men and Women, All Ages, 2017–2027

Figure 18: 7MM, Diagnosed Incident Cases of HSCT-CMV, Men and Women, All Ages, 2017–2027

Figure 19: 5EU and Japan, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017–2027

Figure 20: US, Diagnosed Incident Cases of cCMV, Men and Women, All Ages, 2017–2027

Frequently asked questions

Cytomegalovirus (CMV): Epidemiology Forecast to 2027 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Cytomegalovirus (CMV): Epidemiology Forecast to 2027 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cytomegalovirus (CMV): Epidemiology Forecast to 2027 in real time.

  • Access a live Cytomegalovirus (CMV): Epidemiology Forecast to 2027 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.